STERIS Business Summary

STERIS plc (STE) operates a high-margin, diversified business model centered on infection prevention and procedural solutions for the healthcare, pharmaceutical, and medical device sectors. The company utilizes a "razor-and-blade" revenue strategy, pairing the sale of capital equipment—such as steam sterilizers, surgical tables, and endoscopy systems—with recurring revenue from proprietary consumables and long-term service contracts. Its operations are structured into three core segments: Healthcare, the largest division serving clinical providers; Applied Sterilization Technologies (AST), which provides contract sterilization services for global manufacturers; and Life Sciences, focused on contamination control for pharmaceutical production. Following the 2024 divestiture of its Dental segment, STERIS has consolidated its focus on its high-growth sterilization and surgical portfolios. It maintains a leading global market position, competing directly with Getinge AB, Sotera Health, Fortive’s Advanced Sterilization Products (ASP), and Ecolab, distinguishing itself through its unparalleled vertical integration of equipment manufacturing and outsourced sterilization services. Leadership is currently spearheaded by President and CEO Daniel A. Carestio, a veteran executive who joined the company in 2001 and previously led the AST and Healthcare divisions before his appointment to the top role in 2021. In August 2025, Karen L. Burton, formerly the Vice President and Chief Accounting Officer, transitioned into the role of Senior Vice President and Chief Financial Officer, succeeding long-time CFO Michael Tokich. The executive team is supported by General Counsel J. Adam Zangerle and Independent Chairman Dr. Mohsen M. Sohi, who also serves as the CEO of the Freudenberg Group. Founded in 1985 by Bill R. Sanford, STERIS has evolved into an S&P 500 mainstay with a blue-chip institutional investor base led by The Vanguard Group and BlackRock. The Board of Directors features a high pedigree of industry expertise, including notable members such as Dr. Esther Alegria and former Hospital for Special Surgery CEO Louis A. Shapiro, providing robust governance as the company navigates complex global regulatory landscapes and tariff-related margin pressures.